Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $1.5 per share a year ago.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.1 per share a year ago.
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Clearside Biomedical (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Charlie Deignan - CFO Conference Call Participants Jon Wolleben - Citizens Serge Belanger - Needham & Company Debanjana Chatterjee - JonesTrading Yi Chen - H.C. Wainwright Daniil Gataulin - Chardan Operator Greetings, and welcome to the Clearside Biomedical Fourth Quarter 2024 Financial Results and Corporate Update Call.
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.08 per share a year ago.
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now
Clearside Biomedical (CLSD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Charlie Deignan - CFO Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer Debanjana Chatterjee - JonesTrading Operator Greetings, and welcome to the Clearside Biomedical Third Quarter 2024 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode.
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.
After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
Clearside Biomedical (CLSD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
